Serial No. 10/057/350 Filing Date Examiner Group Art Unit 10/057/350 January 25, 2002 January 26, 2002 January 27, 2002 January 27, 2002 January 28, 2002 Janua	Termina Patenti	l Disclaimer To Obviate A ng Rejection Over A Prior	Double Patent	Docket No. ISPH-0625
Serial No. 10/857,359 Jamasry 25,2002 James Schultz 1635  Invention: ANTISENSE OLICONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION  To the COMMISSIONER FOR PATENTS:  The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend be the expiration date of the full statutory term of any patent granted on the instant application, which would extend be the expiration date of the full statutory term of any patent granted on the instant application and is binding such period that it and the prior patent are commonly owned. This agreement has with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance held under 37 C.F.R. 1.321, has elf claims cancelled by a reexamination cartificate, is reissued, or is in any manner terminated printed statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to act on behalf of the organization.  J hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be tr	In Re Application Of: Br	ett P. Monia		,
Owner of Record: Isis Pharmaceuticals, Inc.  TO THE COMMISSIONER FOR PATENTS:  The above-identified owner of record of a 100 percent interest in the instant application, which would extend be provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend be recorded below, the terminal part of the statutory term of any patent granted on the instant application, which would extend be recorded below. It is supported to the statutory term of any patent granted on the instant application to determine only for and during such period that it and the prior patent are commonly owned. This agreement runs with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above discalimer, the owner does not disclaim the terminal part of any patent granted on the instant application and to the optimization of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance in the interest of the statutory disclaimed in whole or terminally disclaimed and the statutory to the statutory disclaimed in whole or terminally disclaimed and the statutory to the statutory disclaimed in whole or terminally disclaimed for the full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1.  For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to act on behalf of an organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made information and behild are believed to be true; and further that these statements were made with the knowledge that within information and behild are believed to be true; and further that these statements were made with the knowledge that within information a		<del>-</del>		
Owner of Record: Isis Pharmaceuticals, Inc.  TO THE COMMISSIONER FOR PATENTS:  The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend be the expiration date of the full statutory term defined in 35 U.S.C. 164 to 158 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,410,518. The owner hereby agrees that any patent so granted on the instant application be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance in the dumentage scale, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed and the statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to sick on behalf of the organization.  1 hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be true; and further that these statements were made with the knowledge that williful information and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the 1 States Code and that such willful false sta	-	OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EXP	RESSION
To THE COMMISSIONER FOR PATENTS:  The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend be the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any term disclaimer, of prior Patent No. 6.410,518. The owner hereby agrees that any patent as granted on the instant application be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed 37 C.F.R. 1.321, has all claims cancelled by a reexamination critificate, is relissed, or is in any manner terminated prior the expiration of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to act on behalf of the organization.  1 hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be true; and further that these statements were made with the k				
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, exception date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any term disclaimer, of prior Patent No. 6,410,518. The owner hereby agrees that any patent ogranted on the instant application and during such period that it and the prior patent are commonly owned. This agreement runs with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the insplication that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration of a statutority disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is relisated, or is in any manner terminated protection of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be true; and further that these statements were made with the knowledge that with file application or any	Owner of Record: Isls 1	Pharmaceuticals, Inc.		
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, exception date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any term disclaimer, of prior Patent No. 6,410,518. The owner hereby agrees that any patent ogranted on the instant application and during such period that it and the prior patent are commonly owned. This agreement runs with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the insplication that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the application that would extend to the expiration of a statutority disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is relisated, or is in any manner terminated protection of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be true; and further that these statements were made with the knowledge that with file application or any			A SEALTO	
provided below, the terminal part of the statutory term of any pattern granted but necessary to the expiration date of the full statutory term defined in 35 U.S.C. 154 to 158 and 173, as presently shortened by any term the expiration date of the full statutory term defined in 35 U.S.C. 154 to 158 and 173, as presently shortened by any term disclaimer, of prior patent are commonly owned. This agreement runs with patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the insplication that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance of held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed in under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated printer expiration of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc., undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge are true and that all statements made herein of my own knowledge that willful false statements made herein		TO THE COMMISS	SIONER FOR PATENTS:	
1.	application that would externate patent, as presently shortened unenforceable, is four under 37 C.F.R. 1.321, has the expiration of its full state.	and to the expiration date of the full ened by any terminal disclaimer, in nd invalid by a court of competent is all'claims cancelled by a reexan outory term as presently shortened	the event that it later expires for introduction, is statutorily disclair innation certificate, is reissued, o	or failure to pay a maintenance feet med in whole or terminally disclaim
I hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be true; and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the Usatements and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.  2. The undersigned is an attorney of record.  Dated: February 27, 2004  Signature  Jane Massey Ligita  Typed or Prived Name  Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  PTO suggested wording for ferminal disclaimer was unchanged.  Certification under 37 C.F.R.3.73(b) is required if terminal disclaimer is signed by the assignee.			•	
information and belief are believed to be true; and further triate triate statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.  2. The undersigned is an attorney of record.  Dated: February 27, 2004    Signature   Signat	undersigned is empowere	to act on behalf of the organization		· •
Dated: February 27, 2004  Signature Standard Signature Si	information and belief are	believed to be true; and future to	imprisonment or both under S	section 1001 of Title 18 of the Uni
Jane Massey Lights  Typed or Printed Name  Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  PTO suggested wording for terminal disclaimer was unchanged.  Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.	2.  The undersigned	is an attorney of record.		
Jane Massey Lights  Typed or Printed Name  Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  PTO suggested wording for terminal disclaimer was unchanged.  Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.	On Annitracts	)·	Dated: February 27, 20	04
Typed or Printed Name  Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  PTO suggested wording for terminal disclaimer was unchanged.  Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.	-	Signature S		
Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  PTO suggested wording for terminal disclaimer was unchanged.  Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.	Jar	e Massey Ligta		
P32/REV0	Terminal disclair	ner fee under 37 C.F.R. 1.20(d) inc wording for tërminal disclaimer was er 37 C.F.R. 3.73(b) Is required if to ਨੇ	unchangeo.	e assignee.
111 * RCVD AT 2/27/2004 1:01:41 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:856 810 1454 * DURATION (mm-ss):03-12	Committee of the contract of t		· · · · · · · · · · · · · · · · · · ·	P32/REV01
	/11 * RCVD AT 2/27/2004 1:01:41	AM (Eastern Ständard Time) * SVR:USPTO-	EFXRF-1/2 * DNIS:8729306 * CSID:856 81(	0 14 <b>34 * Dura</b> Hon (mm-ss):03-12

0 FC:1814 1/04/5004

Termin Patent	al Disclaimer To Obviate A ing Rejection Over A Prior	Double Patent		Docket No. ISPH-0625
In Re Application Of: B	rett P. Monia			
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner  James Schultz		Group Art Unit 1635
Invention: ANTISENS	E OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EX	PRESSIC	N
	·			
Owner of Record: Isis	Pharmaceuticals, Inc.	3	10022220	HILLIP 00000004 501619
	TO THE COMMISS	ONER FOR PATENTS:		
disclaimer, of prior Patent be enforceable only for ar patent granted on the insta In making the at application that would exter patent, as presently short held unenforceable, is founder 37 C.F.R. 1.321, has	full statutory term defined in 35 to No. 5,744,362. The owner head during such period that it and the term and the properties of the full prove disclaimer, the owner does not to the expiration date of the full ened by any terminal disclaimer, in the invalid by a court of competent as all claims cancelled by a reexample to the proventies all claims cancelled by a reexample to the term as presently shortened to the No. 1.	reby agrees that any patent so the prior patent are commonly on the grantee, its successors and/on the disclaim the terminal part is statutory term as defined in 35 the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is reissued.	whed. Ti or assigns of any pa U.S.C. 15 or failure imed in w	the distant application of the instant tent granted on the instant 4 to 156 and 173 of the prior to pay a maintenance fee, is hole or terminally disclaimed
1. — For submissions	1 or 2 below, if appropriate.  on behalf of an organization (e.g. d to act on behalf of the organization)	, corporation, partnership, univ	versity, go	vernment agency, etc.), the
information and belief are	that all statements made herein believed to be true; and further the o made are punishable by fine or willful false statements may jeopan	nat these statements were made imprisonment, or both, under the contract of th	Section 10	101 of Title 18 of the United
2. The undersigned	is an attorney of record.			
Janyua	Signature	Dated: February 27, 20	004	
Terminal disclair	te Massey Licata .  ed or Printed Name ner fee under 37 C.F.R, 1.20(d) included in the second second in the second second in the	unchanged.	n <b>e</b> assigne	<b>e</b> .

→ PTOBF

Termin Patent	al Disclaimer To Obviate A l ting Rejection Over A Prior )	Double Patent	Docket No. ISPH-0625
In Re Application Of:	rett P. Monia		
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635
Invention: ANTISENS	E OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EX	PRESSION
Owner of Record: Isis	Pharmaceuticals, Inc.		
	TO THE COMMISS	HONER FOR PATENTS:	
provided below, the termit the expiration date of the disclaimer, of prior Patent be enforceable only for a patent granted on the instance in making the a application that would extipatent, as presently shortheld unenforceable, is for under 37 C.F.R. 1.321, hithe expiration of its full stance.	nal part of the statutory term of any to full statutory term defined in 35 L. No. 5,919,773. The owner her and application and is binding upon the ant application and is binding upon the development of the expiration date of the full tened by any terminal disclaimer, in and invalid by a court of competent as all claims cancelled by a reexample at the application as presently shortened to the statutory term as presently term as the statutory term as the statut	J.S.C. 154 to 156 and 173, as reby agrees that any patent so the prior patent are commonly on the grantee, its successors and/ont disclaim the terminal part a statutory term as defined in 35, the event that it later expires for jurisdiction, is statutorly disclaimation certificate, is relssued, or in the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is relssued, or in the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is relssued, or in the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is relssued, or in the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is relssued, or in the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is relssued, or in the event that it later expires for jurisdiction, is statutorily disclaimation certificate, is relssued.	pplication hereby disclaims, except as pplication, which would extend beyond a presently shortened by any terminal granted on the instant application shall owned. This agreement runs with any for assigns.  of any patent granted on the instant is U.S.C. 154 to 156 and 173 of the prior for failure to pay a maintenance fee, is almed in whole or terminally disclaimed or is in any manner terminated prior to
4 — For submissions	x 1 or 2 below, if appropriate. s on behalf of an organization (e.g. ad to act on behalf of the organization	., corporation, partnership, univ	iversity, government agency, etc.), the
I hereby declar information and belief ar statements and the like States Code and that suc	e that all statements made hereing believed to be true; and further the so made are punishable by fine or the willful false statements may jeopal	of my own knowledge are tr hat these statements were made	true and that all statements made on ide with the knowledge that willful false Section 1001 of Title 18 of the United ion or any patent issued thereon.
2. The undersigne	d is an attorney of record.		
Terminal disclai	Signature  Discontinuous Licata  ped or Printed Name imer fee under 37 C.F.R. 1.20(d) incl I wording for terminal disclaimer was der 37 C.F.R. 373(b) is required if te	unchanged.	

Termina Patenti	l Disclaimer To Obviate A ng Rejection Over A Prior	Double Patent	Docket No. ISPH-0625
In Re Application Of: Br	ett P. Monia		
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner  James Schultz	Group Art Unit 1635
	OLIGONUCLEOTIDE MODU	ILATION OF RAF GENE EXI	PRESSION
Owner of Record: Isis P	harmacenticals, Inc.		
	TO THE COMMISS	SIONER FOR PATENTS:	
the expiration date of the fidisclaimer, of prior Patent N be enforceable only for and patent granted on the instant in making the abordant, as presently shorter held unenforceable, is founder 37 C.F.R. 1.321, has	I part of the statutory term of any full statutory term defined in 35 to 6,358,932. The owner he during such period that it and that application and is binding upon to the disclaimer, the owner does not to the expiration date of the full had by any terminal disclaimer, in disclaims cancelled by a reexample of term as presently shortened to	J.S.C. 154 to 156 and 173, as reby agrees that any patent so go he prior patent are commonly ow the grantee, its successors and/o not disclaim the terminal part of statutory term as defined in 35 to the event that it later expires for jurisdiction, is statutorily disclaimination certificate, is relessued, or	presently shortened by any terranted on the instant application when. This agreement runs with assigns.  If any patent granted on the in J.S.C. 154 to 156 and 173 of the or failure to pay a maintenance the med in whole or terminally discland.
	or 2 below, if appropriate.		· ·
1.  For submissions of undersigned is empowered	n behalf of an organization (e.g. to act on behalf of the organization	., corporation, partnership, univen.	ersity, government agency, etc.
information and belief are t	that all statements made herein delieved to be true; and further th made are punishable by fine or willful false statements may jeopar	hat these statements were made imprisonment, or both, under S	e with the knowledge that williu action 1001 of Title 18 of the I
2. The undersigned is	s an attorney of record.	•	
	Signature	Dated: February 27, 200	04
Jane	Massey Licata	_	
Tuned	or Printed Name		